drugset
drugset / Trial / NCT03023423

A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer

NCT03023423 ↗

Phase 1/2 Completed 100 enrolled Janssen Research & Development, LLC Genentech, Inc. · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to compare the overall response rate (ORR) in non-small cell lung cancer (NSCLC) participants treated with daratumumab in combination with atezolizumab versus atezolizumab alone.

Timeline

Start
2016-12-23
Primary completion
2018-05-17
Completion
2019-09-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Atezolizumab Monoclonal antibody 1200 mg Intravenous
Subject Daratumumab Monoclonal antibody 16 mg/kg Intravenous

Indications

non-small cell lung carcinoma